Table 1 TNFR-targeted agents in development
From: Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
TNF receptor molecule | Name | Description | Sponsor | Phase in cancer patients |
|---|---|---|---|---|
4-1BB (CD137) | CART19 cells | T cells transduced with antibody against CD19 linked to the intracellular signaling domains of 4-1BB and CD3-zeta | University of Pennsylvania and others | II |
Urelumab | Fully human anti-CD137 agonist monoclonal antibody | Bristol Myers-Squibb | I | |
OX40 | Â | Mouse monoclonal anti-OX40 agonist antibody | Providence Health & Services and others | II |
| Â | Humanized antibody against OX40 | Â | Preclinical | |
hFcILZOX40L | Recombinant human Fc:OX40L fusion protein | Providence Portland Medical Center | Preclinical | |
GITR | TRX518 | Humanized anti-GITR agonist monoclonal antibody | GITR, Inc. | I |
GITRL RNA DC | GITRL-expressing DCs | Duke University | I | |
CD27 | CDX-1127 | Fully human anti-CD27 agonist monoclonal antibody | Celldex Therapeutics | I |